Project description
AI-driven platform to predict mutagenicity from chemical compounds
Evaluating mutagenicity (the potential of a substance to harm DNA) is vital in drug development to ensure safety. The drug development process is complex, time-consuming and costly. Inadequate assessment of mutagenicity can lead to severe consequences. Effective evaluation can prevent these outcomes and the use of AI and whole genome sequencing can enhance this process. The ERC-funded MUTAPREDICT project aims to create an AI-driven platform that transforms drug development by predicting the mutagenic potential of new chemical compounds. This approach addresses the ethical and economic challenges of traditional animal testing, offering a humane and efficient alternative. The solution accelerates drug development by using advanced whole genome sequencing data while ensuring safety and efficacy.
Objective
Assessing mutagenicity, the capacity of a substance to cause permanent and potentially harmful changes to an organism's DNA, is a pivotal concern in drug development. This assessment is crucial because it helps to predict the carcinogenic potential of new pharmaceuticals, ensuring that they are safe for human use. The importance of evaluating mutagenicity in drug development cannot be overstated. Drugs are designed to interact with biological systems to treat or prevent diseases, but they must do so without causing harmful genetic alterations. The process of developing a new drug involves a complex, time-consuming, and costly sequence of research and testing to ensure efficacy and safety. If mutagenicity is not accurately assessed, the consequences can be severe. Addressing the complexities and limitations associated with assessing mutagenicity in drug development, an innovative approach utilizing artificial intelligence (AI) and whole genome sequencing (WGS) data presents a promising solution. MUTAPREDICT introduces an innovative AI-driven platform designed to revolutionize the field of drug development by accurately predicting the mutagenic potential of new chemical compounds. This platform is set to address the ethical, economic, and temporal challenges associated with conventional animal testing and in vitro analyses, promoting a more humane, cost-effective, and efficient approach to drug safety assessments. Leveraging advanced WGS data, our solution significantly accelerates the drug development process, ensuring both safety and efficacy. Our value proposition encompasses ethical and sustainable drug development by offering a viable alternative to animal testing, thus meeting the growing demands for ethical research practices.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- natural sciences biological sciences genetics DNA
- social sciences other social sciences development studies social developments
- natural sciences biological sciences genetics mutation
- natural sciences biological sciences genetics genomes
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.1 - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2024-POC
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
3584CS Utrecht
Netherlands
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.